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SUMMARY
AML1/ETO results from the t(8;21) associated with 12%–15% of acute myeloid leukemia. The AML1/
ETO MYND domain mediates interactions with the corepressors SMRT and N-CoR and contributes to
AML1/ETO’s ability to repress proliferation and differentiation of primary bone marrow cells as well as
to enhance their self renewal in vitro. We solved the solution structure of the MYND domain and show
it to be structurally homologous to the PHD and RING finger families of proteins. We also determined
the solution structure of an MYND-SMRT peptide complex. We demonstrated that a single amino
acid substitution that disrupts the interaction between the MYND domain and the SMRT peptide
attenuated AML1/ETO’s effects on proliferation, differentiation, and gene expression.INTRODUCTION
AML1/ETO is produced as a result of the t(8;21) found in
acute myeloid leukemia (AML) of the M2 subtype (Miyoshi
et al., 1993). It consists of the N terminus of AML1, includ-
ing its DNA-binding Runt domain, and almost the entire
ETO protein. AML1/ETO causes leukemia in mice in coop-
eration with other mutated genes such as TEL/PDGFRb,
ISCBP deficiency, and the FLT3 internal tandem duplica-
tion (Grisolano et al., 2003; Schessl et al., 2005; Schwieger
et al., 2002). It interacts with many other proteins including
CBFb, SMRT/N-CoR, PLZF, GFI-1, SIN3, and numerous
histone deacetylases (Hug and Lazar, 2004). Determining
which of these interactions contributes to AML1/ETO’s
activity and which pathways are affected by these interac-tions is necessary in order to develop targeted therapy for
this leukemia.
Many of AML1/ETO’s interactions with other proteins
are mediated by the five domains that are conserved
with the Drosophila Runt, Lozenge, and Nervy proteins.
The most N-terminal domain is the Runt domain from
the AML1 fusion partner, which is an s type immunoglob-
ulin fold that binds both DNA andCBFb (Bravo et al., 2001;
Tahirov et al., 2001). DNA binding by the Runt domain is
thought to be essential for AML1/ETO’s leukemogenic
activity (Grisolano et al., 2003). C-terminal to the Runt
domain is the Nervy homology region 1 (NHR1), otherwise
known as the ETO TBP-associated factor homology do-
main (eTAFH) (Zhang et al., 2004). NHR2, or the hydropho-
bic heptad repeat (HHR) domain, is a helical tetramer thatSIGNIFICANCE
Chromosomal rearrangements often result in the production of chimeric proteins with altered function. In many
cases, aberrant recruitment of corepressor complexes has been shown to contribute substantially to the onco-
genic potential of these chimeric proteins. The MYND domain (NHR4) of ETO, responsible for recruitment of the
corepressors SMRT and N-CoR, becomes fused to the AML1 protein as a result of the 8;21 translocation. We
have solved the structure of an MYND domain/SMRT complex. Based on the structural information, we have
used a point mutation to show that SMRT/N-CoR recruitment by the MYND domain plays a key role in the block
in proliferation and differentiation seen with AML1/ETO and alters the expression of genes associated with these
functions.Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 483
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Structure/Function of MYND Domain in AML1-ETOmediates oligomerization with AML1/ETO, ETO, or the
ETO homologs MTG16 and MTGR1 (Kitabayashi et al.,
1998; Liu et al., 2006; Minucci et al., 2000; Zhang et al.,
2004). Oligomerization through the HHR domain appears
to be essential for AML1/ETO’s activity in repressing cell
proliferation and differentiation and in promoting the
clonogenic ability of primary hematopoietic progenitors
(Hug et al., 2002; Liu et al., 2006; Shimada et al., 2000;
Zhang et al., 2001). NHR3 interacts with the regulatory
subunit of type II cyclic AMP-dependent protein kinase
(PKA RIIa) (Fukuyama et al., 2001). Its in vivo contribution
to AML1/ETO function is not well characterized.
NHR4, also known as the myeloid-Nervy-DEAF-1
(MYND) domain was predicted based on its primary se-
quence to have two putative, non-DNA-binding zinc
fingers (Gross and McGinnis, 1996) and binds the silenc-
ing mediator of retinoid and thyroid hormone receptor
(SMRT) and nuclear receptor corepressor (N-CoR) com-
plexes (Gelmetti et al., 1998; Lutterbach et al., 1998a;
Wang et al., 1998). The MYND domain is defined by a
C6HC zinc-chelating motif that is found in a number of
other nuclear proteins such as Nervy, DEAF-1, BS69,
PDCD2, and Bop. MYND domains have frequently been
implicated in transcriptional repression (Ansieau and
Leutz, 2002; Gottlieb et al., 2002; Ladendorff et al.,
2001; Lausen et al., 2004; Scarr and Sharp, 2002; Sims
et al., 2002). Recruitment of N-CoR/SMRT and their asso-
ciated histone deacetylases (HDACs) to AML1 target
genes is one mechanism by which AML1/ETO is thought
to aberrantly repress transcription and contribute to leuke-
mogenesis (Gelmetti et al., 1998; Lutterbach et al., 1998b).
Here we report the solution structure of the AML1/ETO
MYND domain, showing it is structurally homologous to
the PHD and RING finger families of proteins. In addition,
we solved the structure of a complex between the AML1/
ETO MYND domain and a peptide from SMRT. Based on
that structure, we introduced single amino acid substitu-
tions into the AML1/ETO MYND domain to assess the
role of the SMRT/N-CoR interaction in vivo. We show
that mutations that disrupt SMRT/N-CoR binding reverse
AML1/ETO’s repression of cell proliferation, mildly affect
its ability to repress granulocyte differentiation, and atten-
uate alterations in gene expression caused by AML1/ETO
in lineage-negative Sca-1+ c-kit+ (LSK) bonemarrow cells.
RESULTS
Solution Structure of the MYND Domain
from AML1/ETO
The 15N-1H HSQC spectrum of the AML1/ETO MYND
domain (aa 658–707) clearly indicated a structured entity
(Figure 1A), but upon addition of 5 mM EDTA, it collapsed
to a poorly dispersed spectrum characteristic of an un-
folded species (data not shown). Refolding was readily
achieved by dialysis against 50 mM ZnCl2, confirming
that Zn2+ is essential for maintaining the MYND structure.
The putative zinc-chelating residues include cysteines
663, 666, 674, 677, 683, 687, 699, and one of the three
consecutive histidines (695, 696, and 697). To unequivo-484 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.cally identify which histidine is chelated to Zn, we ran a
long range 15N-1H HSQC (Pelton et al., 1993) at pH 6.0
which clearly indicated that the N32 of H695 is resistant
to protonation and thus is the zinc-chelating atom (see
Figure S1A in the Supplemental Data available with this ar-
ticle online). Mutation of H695 to Ala resulted in an HSQC
spectrum similar to that obtained in the presence of EDTA
(Figure S2D and data not shown).
We solved a high-resolution structure of the AML1/ETO
MYND domain using a combination of NOEs, chemical
shifts, and extensive dipolar couplings (Table 1). The over-
all fold of the AML1/ETO MYND domain adopts an inter-
leaved zinc-chelating topology as observed in the PHD
and RING domains. Zinc center I consists of Cys 663,
666, 683, and 687, and zinc center II is formed by Cys
674, 677, 699, and His695 (Figure 1B). The relative posi-
tioning of secondary structure elements follows the bba
motif frequently observed in PHD and RING fingers
(Pascual et al., 2000; Zheng et al., 2002). These structural
features greatly differ from those of the LIM zinc-finger do-
main, which also contains two zinc atoms but adopts a
sequential zinc-chelating topology and forms two juxta-
posed domains with a certain degree of structural similar-
ity (Velyvis et al., 2001).
Spadaccini et al. (Spadaccini et al., 2006) recently
reported that the DEAF-1 MYND domain (backbone
RMSD = 7.8 A˚ to our ETOMYND domain) has a sequential
zinc-chelating topology like that of the LIM domains. This
is a completely different fold than we describe here, which
is surprising given the very high sequence similarity
between MYND domains (Figure 1C). The ETOMYND do-
main structure has been refined and validated with resid-
ual dipolar couplings from two independent alignments.
Fitting only the conserved residues in the DEAF-1 MYND
domain structure to the 19 corresponding NH dipolar cou-
plings obtained for the ETOMYND domain yields an aver-
age Q factor of 84%, i.e., the structure is highly inconsis-
tent with the dipolar couplings measured for the ETO
MYND domain. A more extensive discussion of the differ-
ences between the two structures and the experimental
data that validates the ETO MYND domain structure is
provided in the Supplemental Data, including Figure S3.
The AML1/ETO MYND Domain Recognizes
a ‘‘PPPLI’’ Motif in SMRT and N-CoR
Residues 1031–1273 in repression domain III (RDIII) of
SMRT were previously shown to contain the binding site
for ETO (Zhang et al., 2001). We confirmed that an aa
1031–1273 SMRT polypeptide bound the MYND domain
by HSQC titration (Figure 1A). N-CoR and SMRT are pre-
dicted to be mostly unstructured in their repression do-
mains suggesting a peptide recognition motif. We there-
fore screened a peptide library spanning the SMRT
interacting region using fluorescence anisotropy to iden-
tify the minimal MYND-binding consensus sequence in
SMRT. We identified three consecutive peptides that dis-
played significantly elevated anisotropy in the presence of
the MYND domain (Figure 1D) and share the common se-
quence motif NPPPLI, corresponding to SMRT residues
Cancer Cell
Structure/Function of MYND Domain in AML1-ETOFigure 1. Structure of the ETO MYND Domain and Its Interactions with SMRT and N-CoR
(A) Overlay of 15N-1H HSQC spectra of the free MYND domain (red) and MYND + SMRT1031-1273 (blue) collected at pH 6.0 and 37C at 500 MHz.
(B) Overlay of the backbone of 31 conformers representing the solution structure of the MYND domain with a helical residues (S685–H695) in red,
b sheet residues (E672–T673 and R681–Y682) in cyan, zinc-chelating side-chains in blue, zinc-chelating atoms in yellow, and zinc atoms in green.
(C) Sequence alignment of MYND domains (Zn-chelating residues in red, additional conserved residues in green and brown) and interacting regions
from SMRT and N-CoR (identical residues in red, conserved residues in green).
(D) Fluorescence anisotropymeasurements on 70 fluorescein-labeled peptides spanning residues 1031–1273 of SMRT. The y axis corresponds to the
difference between the anisotropy in the presence and absence of the MYND domain.
(E) Isothermal titration calorimetry (ITC) measurements of MYND domain binding to peptides derived from SMRT and N-CoR.Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 485
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Structure/Function of MYND Domain in AML1-ETOTable 1. Statistics for NMR Data Collection and Structure Calculations
MYND SMRT-MYND
Total NOEs observed 959 1922
Total nonredundant NOEs 505 964
Intraresidue (i = j) 169 309
Sequential (ji  jj = 1) 129 210
Medium-range (1 < ji  jj < 5) 79 126
Long-range (ji  jj > 4) 128 319
NOES between SMRT and MYND NA 121
Total restraints for zinc chelation 25 25
Dihedral angle restraints
F 15 17
J 15 17
X1 17 16
Total RDCs for structural calculation
HN 33 34
NC0 29 30
C0Ca 30 32
Total RDCs for structural validation (Qfree)*
HN 28 31
RMSD of distance restraints (maximum) (A˚) 0.001 ± 0.000 (0.055) 0.0033 ± 0.0005 (0.099)
RMSD of dihedral angles (maximum) () 0.507 ± 0.033 (2.838) 0.608 ± 0.034 (4.203)
RMSD of RDC (Hz)
HN 0.911 ± 0.012 0.828 ± 0.038
NC0 0.258 ± 0.003 0.165 ± 0.009
C0Ca 0.624 ± 0.005 0.443 ± 0.013
RMSD of covalent geometry
Bond lengths (A˚) 0.001 ± 0.000 0.001 ± 0.000
Bond angles () 0.383 ± 0.005 0.353 ± 0.004
Impropers () 0.240 ± 0.006 0.239 ± 0.005
Qfree* 0.192 ± 0.004 0.185 ± 0.002
Ramachandran plot statistics (%) residues 661–700 residues 661–700 (MYND), 1105–11 (SMRT)
Most favored 78.2 79.9
Additionally allowed 20.4 19.8
Generously allowed 1.3 0.3
Disallowed 0 0
RMSD for NMR ensemble (A˚) residues 661–700 residues 661–700 (MYND), 1105–11 (SMRT)
Backbone 0.18 0.14
Heavy atoms 0.72 0.61
*Qfree is calculated as described previously (Cornilescu et al., 1998) except that the RDCs are used only for validation but not for
structure calculation.1104–1109. A sequence similarity search revealed a simi-
lar binding site with the sequence PPPLI in N-CoR (aa
1033–1037). Isothermal titration calorimetry (ITC) was em-
ployed to determine the stoichiometry and binding affinity486 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.between the MYND domain and the SMRT and N-CoR
peptides (Figure 1E). A further sequence matching in N-
CoR and SMRT using a looser standard yielded one more
potential binding site in both proteins: N-CoR 606–615
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Structure/Function of MYND Domain in AML1-ETOand SMRT 1664–1673 (Figure 1C). Interaction of the
MYND domain with SMRT 1664–1673 was confirmed by
an HSQC titration that showed similar chemical shift
changes as seen for SMRT 1101–1113, though the affinity
appeared weaker (data not shown).
Solution Structure of the SMRT-MYND Complex
We attempted to solve the structure of a MYND domain/
SMRT peptide complex; however, half-filtered NOESY
spectra of a differentially labeled complex (13C/15N-
MYND + unlabeled SMRT) yielded only 12 intermolecular
NOEs, which were insufficient to define the structure of
the complex. Complexes with modest affinity often suffer
from limited intermolecular NOE information due to signif-
icant off rates. To decrease the off rate and thereby facil-
itate the collection of NOE data, we fused the SMRT pep-
tide sequence (SMRT 1101–1113) to the N terminus of
the MYND domain (AML1/ETO 658–707) with a 7 aa linker
(ENLYFQG) between them (subsequently referred to as
SMRT-MYND). This coupling served to increase the effec-
tive local concentration of the SMRT peptide and resulted
in longer residence times and increased NOEs. 15N-1H
HSQC spectra of SMRT-MYND showed that resonances
from the MYND portion of SMRT-MYND overlapped with
resonances from the MYND + SMRT noncovalent com-
plex, but not with those of the free MYND domain (Fig-
ure S1B). Furthermore, the 12 NOEs previously identified
in the noncovalent complex were all present in NOESY
spectra of SMRT-MYND (data not shown), indicating
that the fusion did not change the mode of interaction. In-
deed, {1H}15N NOE measurements showed that the linker
region is flexible, while the MYND and SMRT portions of
the fusion protein display the same dynamic behavior
as one another, consistent with a well-formed complex
(Figure 2A).
The structure ofMYND-SMRT showed that SMRT binds
in an extended conformation to a hydrophobic pocket in
MYND (Figure 2B), burying a total solvent-accessible sur-
face area of 476 A˚2. L1108, I1109, and S1110 from SMRT
form a short antiparallel b sheet with E672, T673, and
C674 of the MYND domain, delineated by four interstrand
hydrogen bonds (Figure 2C). The side chain of L1108
protrudes deep into the hydrophobic pocket of MYND
(Figure 2B). This provides a structural rationalization for
the importance of Leu at this position, which has been
noted by others (Lausen et al., 2004). P1105 packs its
side chain on top of W692 of MYND (Figure 2C). Such a
proline-tryptophan packing arrangement has been fre-
quently observed in protein-protein interactions (Glaser
et al., 2001). Another residue showing 100% conservation
among MYND domains is Q688, which forms a hydrogen
bond to the CO of SMRT P1106 through H322 (Figure 2C).
S675 also has a high degree of conservation among
MYND domains (Figure 1C). The S675 g proton poten-
tially forms a hydrogen bond with L1108 CO of SMRT. In-
deed this g proton undergoes unusually slow exchange
with water and displays a downfield shifted chemical shift
of 6.47 ppm in MYND-SMRT, indicative of hydrogen
bonding.Mutations in the MYND Domain Disrupt SMRT
Peptide Binding
We used the structure of the SMRT-MYND complex to ra-
tionally design mutations that disrupt SMRT/N-CoR bind-
ing in order to examine the importance of this interaction
for AML1/ETO’s function. H695 is a zinc-chelating resi-
due, and 15N-1H HSQC spectra showed the MYND do-
main structure was severely disrupted upon substitution
of H695 with Ala (Figure S2D), resulting in a protein which
cannot bind to the SMRT peptide. Substitution of H689
with Ala, on the other hand, had little or no effect on either
the structure or on SMRT binding (Figure S2D and Fig-
ure 3A). The W692A mutation resulted in perturbations
only of spatially proximal residues in the 15N-1H HSQC
spectrum (Figure 3B and Figure S2A), consistent with
this mutation causing no significant change in the protein
structure. Substitution of W692 with Ala substantially
blocked binding to the SMRT peptide, increasing the Kd
more than 12-fold (Figure 3A). Ala substitutions for Q688
and S675 preserved the MYND structure (Figures S2B
and S2C) and impaired SMRT peptide binding 12-fold and
2.5-fold, respectively (Figure 3A).
Despite the fact that the W692A and H695A mutations
decreased binding of the isolated MYND domain to the
SMRT peptide, we were unable to detect a difference in
full-length AML1/ETO’s ability to coimmunoprecipitate
full length SMRT or N-CoR when proteins containing ei-
ther of these two mutations were overexpressed in Cos7
cells (data not shown). This was not entirely unexpected
since we previously found that a C-terminal truncation of
AML1/ETO that removed both the Nervy and MYND do-
mains entirely did not affect SMRT or N-CoR binding using
the same approach (Liu et al., 2006). AML1/ETO can oligo-
merize with itself, ETO, and the ETO homologs MTGR1
and MTGR2 (MTG16) (Kitabayashi et al., 1998; Liu et al.,
2006; Minucci et al., 2000; Zhang et al., 2001). Therefore,
our inability to detect an effect of the MYND mutations in
coimmunoprecipitation assays could be due to AML1/
ETO’s ability to form mixed tetramers with endogenous
ETO homologs that have intact MYND domains. In addi-
tion, a second N-CoR binding site was mapped to se-
quences between eTAFH and HHR (Amann et al., 2001),
which could also explain the retention of N-CoR and
SMRT binding by the full-length, MYND-mutated AML1/
ETO proteins.
Contribution of the MYND-SMRT/N-CoR
Interaction to AML1/ETO Function
Previous studies showed that deletion of the MYND do-
main impaired AML1/ETO’s ability to repress the differen-
tiation of established hematopoietic cell lines (Gelmetti
et al., 1998; Klampfer et al., 1996; Lutterbach et al., 1998a).
However, in primary bone marrow cells, the MYND do-
main’s contribution to AML1/ETO’s repression of granulo-
cyte differentiation and proliferation and to its ability to
confer serial replating was only observed when coupled
to an HHR domain deletion (Hug et al., 2002). We trans-
duced primary, lineage-depleted (CD5, B220, Mac-1,
Gr-1, Ter119, and Lin) mouse bone marrow cells withCancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 487
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Structure/Function of MYND Domain in AML1-ETOFigure 2. Structure of SMRT-MYND
(A) Left: Overlay of the backbone of 10 conformers representing the solution structure of SMRT-MYND. Residues with {1H}15N NOE > 0.6 in blue,
residues with {1H}15N NOE < 0.6 in red, and residues with no {1H}15N NOE information in green. Right: Overlay of the backbone of 25 conformers
of SMRT-MYND, showing only the structured portion of the protein. The MYND domain is black with helical residues in red and b sheet residues
in cyan. SMRT is gold with b sheet residues in cyan.
(B) Surface representation of the MYND domain with SMRT peptide bound. Electrostatic potential mapped onto surface (blue, positive electrostatic
potential; red, negative electrostatic potential).
(C) Left: Sequence-specific interactions between the MYND domain and SMRT illustrating the stacking of MYND W692 and SMRT P1105, the
hydrogen bond between MYND Q688 and SMRT P1106, and the hydrogen bond between MYND S675 and SMRT-P1107. Hydrogen bonds are
displayed as blue dotted lines. Colors are the same as in the right figure in panel (A). Twenty-five conformers are shown. Right: Schematic illustration
of the observed hydrogen bonds between MYND (red) and SMRT (blue). Backbone-backbone hydrogen bonds are black and sidechain-backbone
hydrogen bonds are green.retroviruses expressing green fluorescent protein (GFP)
alone (MIGR1), AML1/ETO, or an AML1/ETO protein trun-
cated immediately N-terminal to the MYND domain
(W664X) (Figure 3C) and assessed granulocyte differentia-
tion after 7 days of culture in the presence of IL-3, IL-6,
SCF, and G-CSF in the successfully transduced (GFP+)
cells. Consistent with data reported by Hug et al. (Hug
et al., 2002), we observed that deletion of the entire
MYND domain and sequences C-terminal to it did not
impair AML1/ETO’s ability to inhibit the differentiation of
Gr-1+ Mac-1+ cells from Lin bone marrow cells in vitro
(Figures 3D and 3E). We therefore mutated seven Leu res-
idues in the HHRdomain at the tetramer interface that pre-488 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.vent its oligomerization (m7) (Liu et al., 2006) and assessed
the effects of the MYND mutants in the context of the m7
HHR mutation. As we showed previously (Liu et al., 2006),
the m7 mutation partially ameliorated AML1/ETO’s in-
hibition of granulocyte differentiation, and deletion of the
MYND domain in the context of this m7 mutation further
weakenedAML1/ETO’s negative effect ongranulocyte dif-
ferentiation (Figures 3D and 3E). The W692A and H695A
mutations in the context of the m7 mutation also signifi-
cantly impaired, but did not completely reverse, AML1/
ETO’s repression of granulocyte differentiation (Figures
3D and 3E). All three m7 + MYND mutant AML1/ETO pro-
teins accumulated to the same level as the m7 mutant in
Cancer Cell
Structure/Function of MYND Domain in AML1-ETOretrovirally transduced NIH3T3 cells (Figure 3F). We could
not detect the proteins by western blot in the transduced
primary bone marrow cells (data not shown).
AML1/ETO inhibits the short-term proliferation of hu-
man and mouse primary bone marrow cells (Hug et al.,
2002; Mulloy et al., 2002). It was previously reported that
deletion of the MYND domain had no effect on AML1/
ETO’s antiproliferative activity (Hug et al., 2002). In our
hands, deletion of theMYNDdomain (W664X) ameliorated
this antiproliferative effect, although the percentage of
cells that incorporated BrdU was still significantly lower
than for MIGR1 transduced cells (Figure 3G). Both the
H695A and W692A mutations alleviated AML1/ETO’s re-
pressive effect on proliferation to a similar extent as the
W664X truncation (Figures 3G and 3H).
Deletion of the MYND domain did not affect AML1/
ETO’s ability to confer increased self-renewal capacity
on hematopoietic progenitors in vitro, consistent with data
from Hug et al. (Hug et al., 2002) (data not shown), so pre-
sumably the W692A and H595A mutations would also not
affect AML1/ETO’s serial replating activity, although we
did not examine this directly. Since in our hands, the m7
mutation in the HHR domain destroyed AML1/ETO’s abil-
ity to confer increased self-renewal (Liu et al., 2006), we
could not use the m7 mutant as a sensitized background
upon which to further examine the effects of the W692A
and H695A mutations.
Loss of the MYND-SMRT/N-CoR Interaction
Attenuates the AML1/ETO Signature in LSK Cells
To gain insights into themolecular basis bywhich eliminat-
ing SMRT/N-CoR binding through the MYND domain
relieves the proliferation block caused by AML1/ETO in
Lin bonemarrow cells but not its ability to confer serial re-
plating capacity, we analyzed the effect of theW692Amu-
tation on gene expression changes caused by AML1/ETO.
We prepared Lin Sca-1+ mouse bone marrow cells, sub-
divided them into 11 pools, and independently transduced
these cell poolswithMIGR1, AML1/ETO, or theAML1/ETO
W692Amutant (Figure 4A). Two days later,25,000 trans-
duced (GFP+) LinSca1+ c-kit+ (LSK) cells from each sam-
ple were sorted by FACS into RNA lysis buffer for RNA pu-
rification, labeling, and hybridization to Affymetrix Mouse
Genome 430 2.0 arrays (Figures 4A and 4B). We drew
a wide gate around the Sca-1 population for sorting pur-
poses (Figure 4B) because cell surface Sca-1 levels varied
considerably between samples (Figure 4F).
We uploaded the raw expression data to Iobion Infor-
matic’s GeneTraffic v. 3.2 server (Irizarry et al., 2003)
and set expression values from the three MIGR1-trans-
duced samples as the baseline for comparison to AML1/
ETO andW692A transduced samples. Unsupervised clus-
tering separately grouped the MIGR1, AML1/ETO, and
W692A samples, indicating that the three gene profiles
were significantly different (data not shown). We screened
the data by significance analysis of microarrays (SAM)
(Tusher et al., 2001) and found genes corresponding to
2229 probe sets were differentially expressed in AML1/
ETO-transduced LSK cells as compared to LSK cellstransduced with MIGR1 alone (Figure 4C). These included
genes previously reported to be dysregulated in the pres-
ence of AML1/ETO in myelomonocytic cell lines (Alcalay
et al., 2001; Shimada et al., 2000; Yan et al., 2004) (Fig-
ure 4E). One upregulated gene was Ly6a, which encodes
the Sca-1 protein, and, indeed, increased levels of Sca-1
were detected on AML1/ETO-transduced LSK cells (Fig-
ure 4F). c-kit, on the other hand, was not differentially ex-
pressed either at themRNA (data not shown, inferred from
microarray data) or protein level (Figure 4F).
A smaller number of genes (823 probe sets) were differ-
entially expressed in LSK cells transduced with the AML1/
ETOW692Amutant as compared to LSK cells transduced
with MIGR1 (Figure 4C). We compiled the two probe sets
(AML1/ETO versus MIGR1 plus W692A versus MIGR1)
into a single ‘‘master’’ list. There was considerable overlap
between the two probe sets, thus themaster list consisted
of 2444 probe sets representing 1727 annotated genes
(Figures 4C and 4D and Tables S1 and S2). We screened
the 1727 annotated genes by SAM to identify those that
were differentially regulated by AML1/ETO versusW692A,
which yielded a list of 1231 genes (Figure 4C and Table S2).
The expression of 1113 (90%) of these differentially ex-
pressed genes was attenuated by the W692A mutation.
The remaining 118 differentially expressed genes were
either dysregulated in the opposite direction by AML1/ETO
and the W692A mutant, or dysregulated to a greater extent
by the AML1/ETO W692A protein than by AML1/ETO.
Thus, the most prominent pattern was that the W692A
mutation attenuated AML1/ETO’s activity (Table S2).
A trivial explanation for attenuated activity would be that
the relative levels of the AML1/ETO W692A protein were
lower. Unfortunately, we were unable to detect either the
AML1/ETO or W692A proteins by western blot analysis
of purified GFP+ cells from retrovirally transduced primary
bonemarrow cells and therefore could not directly rule out
this possibility. However, the levels of the bicistronic
mRNAs encoding the AML1/ETO and W692A proteins
were similar, based both on the intensity of GFP fluores-
cence (data not shown) and by qRT-PCR analysis (Fig-
ure S5). It still remains possible that the W692A protein
accumulated at lower levels in LSK cells because it was
no longer stabilized by the association with protein com-
plexes normally recruited by the MYND domain.
We identified 496 genes (28.7% of the master gene list)
whose expression was dysregulated to the same extent
by AML1/ETO and the W692A mutant (Figure 4C and
Table S2). Therefore, if the W692A mutation did affect
AML1/ETO protein levels, it impacted the expression of
some genes and not others.
We identified79 cell-cycle-related geneswhoseexpres-
sionwasaffected to a relatively small (ranging from1.51- to
5.4-fold) but significantly different extent by AML1/ETO
and the W692A mutant (Table 2). The differential expres-
sion of these genes presumably contributes to the major
biological difference we observed, namely the repression
of proliferation by AML1/ETO and the relief of that repres-
sion by the W692A mutation. The more minor effects
we observed in granulocyte differentiation correlate withCancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 489
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Structure/Function of MYND Domain in AML1-ETOFigure 3. AML1/ETO Function Is Impaired by Mutations in the MYND Domain that Disrupt SMRT Binding
(A) Fluorescence anisotropy measurements of the SMRT1031-1273 fluorescein-labeled peptide binding with MYNDmutants. Plot shows normalized
change in occupancy (or normalized change in anisotropy) using the equation [FA(mutant)  FA(H695A)]/[FA(WT)  FA(H695A)], where FA(mutant),
FA(H695A), and FA(WT) stand for the fluorescence anisotropy values of the peptide in the presence of the mutant MYND, of H695A MYND, and of
wild-type MYND, respectively. Since H695A is unfolded, the fluorescence anisotropy in the presence of this protein was used as the zero point to
correct for the effects of increased viscosity with increasing protein concentration, rather than the value for the peptide alone, on the fluorescence
polarization measurement. SMRT peptide concentration was kept at 1 mM and WT and mutant MYND domains at 161 mM. Binding constants of
the mutants relative to that of WT were calculated as (([mutant]total + KD(mutant))/[mutant]total)/(([WT]total + KD(WT))/[WT]total) = (FA(WT) 
FA(H695A))/(FA(mutant)  FA(H695A)), where [mutant]total = [WT]total = 161 mM, and KD(WT) = 109.4 mM based on ITC. Error bars represent the
mean ±SD for three independent measurements.
(B) Structure of the MYND domain illustrating the localized chemical shift perturbations caused by the W692A mutation. NH atoms are colored as
follows: NH chemical shift change >0.1 ppm, red; NH chemical shift change between 0.04 and 0.1 ppm, orange; NH chemical shift change <0.04
ppm, blue; unassigned, black. The side chain of W692 is shown in purple.
(C) Schematic diagram of AML1/ETO and the truncated W664X mutant. Sequences derived from AML1 are brown, and those from ETO are blue.
(D) Representative flow of Lin BM cells infected with MIGR1 retroviruses expressing AML1/ETO and mutated derivatives following seven days of
culture in the presence of IL3, IL6, SCF, and G-CSF. Cells within the forward and side scatter gates were further gated for GFP expression, and
GFP positive cells examined for Mac-1 and Gr-1 expression. The experiments were performed twice with triplicate samples.
(E) Average percentages of Gr-1+Mac-1+ cells (±SD) from a representative experiment with triplicate samples.
(F) Western blot probed with an antibody to the Runt domain, demonstrating expression of the m7 AML1/ETO HHR mutant and mutated MYND
derivatives thereof in retrovirally-transduced NIH3T3 cells.490 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.
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process (Table 3).
DISCUSSION
The structure of the MYND domain/SMRT peptide com-
plex provided insights into how specificity is achieved
and structure-based mutations enabled us to assess the
contribution of SMRT/N-CoR binding through the MYND
domain to AML1/ETO function. As is the case with other
domains such as SH3 and WW that bind to Pro-rich
sequences, the question arises how specificity can be
achieved with a binding motif consisting exclusively of
nonpolar residues that cannot form specific hydrogen
bonds or electrostatic interactions. In the case of the
MYND domain/SMRT (N-CoR) binding, specificity is
achieved through a combination of proline-tryptophan
packing interactions, other van der Waals interactions
via the complementary surfaces, and by means of the
conformational rigidity of the Pro-rich sequence that min-
imizes the entropic cost of binding and positions back-
bone nuclei favorably for hydrogen bond formation. The
first Pro in the ‘‘PPPLIP’’ motif packs against W692. The
carbonyls of the second and third prolines form hydrogen
bonds with Q688 and S675, respectively. Although hy-
drogen bonds to the backbone generally cannot provide
specificity, the relative geometrical positions of W692,
Q688, and S675 on the MYND domain favor substrates
with a certain backbone conformation for hydrogen bond
formation. N-CoR binds the MYND domain with higher
affinity than SMRT, and the only difference in the directly
interacting region is that P1038 of N-CoR, which is one
of the three consecutive residues forming a b strand with
the MYND domain, is replaced by S1110 in SMRT.
S1110, with its HN pointing away from the b strand,
does not seem to participate in any specific interaction,
and it is not obvious why a Pro at this position increases
binding affinity. It is tempting to speculate that MYND’s
higher affinity for N-CoR is because the proline reduces
the entropic penalty for binding. Indeed, ITC data show
that DH is quite similar for the MYND/N-CoR and MYND/
SMRT interactions (9883 cal mol1 and 9836 cal
mol1, respectively) while it is DS that dominates the dif-
ference in binding affinity (–12.4 cal mol1 K1 and –14.5
cal mol1 K1, respectively).
Using the structural information, we introduced muta-
tions in the AML1/ETOMYNDdomain that specifically dis-
rupted SMRT (and presumably N-CoR) binding without
significantly affecting theMYNDdomain structure. Impair-
ing SMRT/N-CoR binding to the MYND domain attenu-
ated AML1/ETO’s activity only very modestly in primary
bone marrow cells, as had been shown by others using
an MYND domain deletion (Hug et al., 2002). AML1/ETO’sacute repression of cell proliferation was alleviated but not
completely eliminated, and its negative effect on granulo-
cyte differentiation was ameliorated, but only in the con-
text of a mutation that impaired oligomerization. In fact,
the presence of an oligomerization domain (HHR) in
AML1/ETO complicates efforts to document the impor-
tance of other ETO sequences for AML/ETO’s activity
since the formation of mixed tetramers with endogenous
ETO or the ETO homologs MTGR1 and MTGR2 could
dampen a mutation’s effects. Nevertheless, the effect of
a single amino acid substitution that decreased SMRT/
N-CoR binding by 12-fold was relatively extensive, at least
with respect to the number of genes (1231) whose expres-
sion was significantly different by SAM analysis. Presum-
ably included among these are genes whose differential
expression underlies the perturbations in proliferation
and granulocyte differentiation that were observed by us
and others (Gelmetti et al., 1998; Hug et al., 2002; Klamp-
fer et al., 1996).
Cell-cycle-related genes that were differentially ex-
pressed included those with established roles in cell-cycle
regulation and checkpoint control, DNA repair, DNA repli-
cation, and mitosis. Many genes listed in Table 2 promote
these processes and were downregulated in the presence
of AML1/ETO, with this effect attenuated by the W692A
mutation. Conversely, several genes that negatively regu-
late cell-cycle progression or proliferation (Ccng2, G0s2,
Tgfb1) were upregulated by AML1/ETO and less so by the
AML1/ETO W692A mutant. The largest absolute change
in expression among this group was observed for Vegfc
which is 75-fold upregulated with AML1-ETO and attenu-
ated to 14-fold with AML1-ETOW692A. Elevated levels of
VEGF have been observed for AML patients and correlate
with reduced survival as well as reduced complete remis-
sion rates in these patients (Aguayo et al., 2000, 2002),
arguing for the potential applicability of antiangiogenic
therapy in t(8;21) leukemia.
AML1/ETO expression also resulted in the downregula-
tion of genes involved in myeloid cell differentiation (Table
3). The most highly differentially expressed gene in this
group isGfi1, which promotes T cell proliferation, granulo-
cyte maturation, restricts the proliferation, and thus main-
tains the quiescence of hematopoietic stem cells (Hock
and Orkin, 2006). Gfi1 expression was upregulated by
AML1/ETO (5.3-fold), and that upregulation was attenu-
ated by theW692Amutation. Cebpa, a known suppressor
of leukemogenesis and positive regulator of granulopoie-
sis (Nerlov, 2004), was downregulated 8.3-fold in the pres-
ence of AML1/ETO, and that repression was alleviated by
the W692A mutation.
Some of the more interesting genes are likely to be
those that are highly dysregulated by both AML1/ETO
and the W692A mutant. Deletion of the MYND domain(G) BrdU incorporation 48 hr after transduction of Lin bonemarrow cells withMIGR1 expressing GFP, AML1/ETO, or the AML1/ETOMYNDmutants.
GFP+ cells were analyzed for BrdU and 7-AAD incorporation following a 1 hr BrdU pulse. No differences in sub G1 (apoptotic) cells were observed.
Shown is a representative of three experiments.
(H) Average percentage of gated BrdU+ cells from scatter plots in panel G (±SD) (n = 3). All samples were significantly different (p% 0.01) from either
MIGR1 or AML1/ETO transduced cells.Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 491
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Structure/Function of MYND Domain in AML1-ETOFigure 4. Gene Expression Profiles of LSK Cells Expressing AML1/ETO nd the AML1/ETO W692 Mutant
(A) Experimental scheme.
(B) Isolation of the retrovirally transduced (GFP+) LSK cells used for microarray analyses.
(C) Microarray data analysis. Expression values from the three MIGR1-transduced samples were set as the baseline for comparison to AML1/ETO-
and AML1/ETOW692A-transduced samples. The AML1/ETO and AML1/ETOW692A data were filtered to remove all genes without at least 3 obser-
vations of log2 ratio = 0.58 (1.5-fold) from MIGR1 samples, yielding 6034 probe sets. SAM performed on AML1/ETO versus MIGR1 with a false dis-
covery rate (FDR) of 0.01% identified 2229 significant probe set changes. SAM on AML1/ETOW692A versus MIGR1 with an FDR of 0.03% identified
823 significant changes. These were combined to yield a master list of 2444 probe sets, which are provided in Table S1. The 2444 probe sets were
manually filtered, removing those corresponding to nonannotated sequences, ‘‘hypothetical proteins,’’ ‘‘cDNA sequences,’’ and ‘‘expressed se-
quences.’’ In addition, for genes whose expression was reported as significant by multiple probe sets, only one probe set was included in the sub-
sequent data analyses. The filtered list contained 1727 annotated genes (Table S2). SAMwas performed on these 1727 genes to compare expression
changes caused by AML1/ETO and AML1/ETO W692A (relative to MIGR1) with FDR = 1.16%, from which 1231 genes that were significantly differ-
ently expressed and 496 genes that were not significantly differently expressed were identified (Table S2).
(D) Unsupervised hierarchical clustering of the master list of 1727 genes using the average clustering of Pearson correlation coefficient, depicted as
a heat map. Yellow represents genes overexpressed relative to the average level in the threeMIGR1-transduced samples, and blue represents under-
expressed genes.
(E) Examples of previously identified genes (Shimada et al., 2000; Yan et al., 2004) differentially regulated by AML1/ETO in LSK cells.
(F) Histograms documenting cell surface expression of Sca-1 and c-kit on the transduced LSK cells.492 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.
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Structure/Function of MYND Domain in AML1-ETOTable 2. Cell-Cycle Related Genes DysregulatedR2-
Fold by AML1/ETO and to a Lesser Extent or Not at All
by the AML1/ETO W692A Mutant
Gene
Symbol
Fold Change
AML1/ETO
Fold Change
AML1/ETO W692A
Il1a 5.86 1.08
Vegfc 75.06 14.32
Cxcl1 9.51 2.00
Il1b 8.13 2.48
Dst 6.79 2.44
G0s2 3.55 1.42
Sash1 4.17 1.69
Mcm2 3.25 1.38
Jun 4.86 2.08
Ranbp1 2.37 1.02
Rprm 2.75 1.19
Fancd2 2.69 1.18
Mycn 4.13 1.81
Ccdc5 2.70 1.22
Ccna2 2.83 1.29
Tacc3 2.89 1.32
Exo1 3.56 1.64
Skp2 2.50 1.16
Gas2l1 2.91 1.37
Ckap2 2.71 1.29
Bub1b 2.45 1.17
Prc1 2.35 1.13
Ccnb1 2.12 1.02
Itgb1 2.23 1.08
Gsg2 3.03 1.47
Pdgfa 2.27 1.11
Ccng2 2.28 1.12
Mcm6 2.28 1.13
Bub1 2.57 1.29
Aurkb 3.23 1.63
Fbxo5 2.10 1.07
Rad51 2.34 1.20
Cdca5 2.23 1.15
App 3.23 1.67
Ris2 2.24 1.17
Sesn1 2.35 1.24
Sgol1 2.27 1.20
Mcm7 2.37 1.27
Fos 13.12 7.04
Tgfb1 4.25 2.34Table 2. Continued
Gene
Symbol
Fold Change
AML1/ETO
Fold Change
AML1/ETO W692A
Aatf 2.76 1.53
Chek1 2.49 1.38
Dusp1 3.27 1.84
Racgap1 2.37 1.36
Mapk3 2.58 1.50
Rras 2.54 1.50
Topbp1 2.66 1.57
Mcm8 2.53 1.49
Sesn3 3.06 1.86
Cdc45l 2.11 1.28
Kif11 2.39 1.46
Dnajc2 2.14 1.30
Mad2l1 2.08 1.26
Mcm3 2.96 1.80
Ran 2.25 1.38
Mlh1 2.12 1.34
Spag5 2.46 1.55
Incenp 2.67 1.69
Cdc7 2.65 1.69
Tfdp1 2.18 1.39
Elk3 2.40 1.55
Ppp3ca 2.26 1.47
Atm 2.68 1.75
Nbn 2.31 1.57
Casp3 2.31 1.59
Tube1 2.58 1.78
Rassf5 2.42 1.68
Ccnd1 3.82 2.73
Ddx11 2.20 1.58
Pard6g 2.35 1.69
Mre11a 2.80 2.03
Rbl1 2.18 1.60
Atr 2.45 1.83
Myc 2.36 1.84
Hus1 2.22 1.80
Ccnt2 2.14 1.77
Genes are listed in the order of the magnitude difference
between AML1/ETO and AML1/ETO W692A (down to a 1.2-
fold difference). Fold change represents the difference in
fold expression relative to MIGR1-transduced LSK cells. The
shaded area indicates genes whose fold expression differ-
ence isR2.Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 493
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Structure/Function of MYND Domain in AML1-ETOTable 3. Genes Involved inMyeloid Cell Differentiation and/or Function that Were Differentially Expressed by AML1/
ETO (R2-fold) and the AML1/ETO W692A Mutant
Gene Symbol Gene Name
Fold Change
AML1/ETO
Fold Change
AML1/ETO W692A
Gfi1 growth factor independent 1 5.28 1.16
Il4 interleukin 4 4.59 1.16
Cbfa2t3h core-binding factor, runt domain, alpha subunit 2, translocated to,
3 homolog (human)
6.05 2.01
Cebpa CCAAT/enhancer-binding protein (C/EBP), alpha 8.32 2.82
Cxcl4 chemokine (C-X-C motif) ligand 4 3.60 1.41
Nfe2 nuclear factor, erythroid derived 2 8.07 3.30
Pirb paired-Ig-like receptor B 2.86 1.21
Trem3 triggering receptor expressed on myeloid cells 3 2.88 1.31
Myadm myeloid-associated differentiation marker 2.66 1.23
Mitf microphthalmia-associated transcription factor 2.60 1.27
Ncor2 nuclear receptor corepressor 2 3.69 1.81
Ngp neutrophilic granule protein 9.11 4.49
Plscr1 phospholipid scramblase 1 4.07 2.07
Ifi203 interferon-activated gene 203 2.46 1.28
Mlf1ip myeloid leukemia factor 1 interacting protein 2.27 1.20
Cd300lf CD300 antigen like family member F 2.23 1.28
Hmgb3 high mobility group box 3 2.72 1.70
Spib Spi-B transcription factor (Spi-1/PU.1 related) 2.22 1.47
Mcl1 myeloid cell leukemia sequence 1 2.09 1.46
Bcl11a B cell CLL/lymphoma 11A (zinc finger protein) 4.18 3.07
Tirap toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 3.97 2.92
Gfi1b growth factor-independent 1B 3.55 2.61
Runx1 runt-related transcription factor 1 2.49 1.83
Genes are listed in the order of the magnitude difference between AML1/ETO and AML1/ETOW692A. Fold change represents the
difference in fold expression relative to MIGR1-transduced LSK cells. The shaded area indicates genes whose fold expression
difference between AML1/ETO and W692A isR2.did not affect one of AML1/ETO’s most important proper-
ties, that is its ability to confer serial replating to primary
bone marrow cells, which is a readout of self renewal po-
tential (Hug et al., 2002). Furthermore, a truncated form
of AML1/ETO or a naturally occurring splice variant that
lacks both the Nervy and MYND domains was leukemo-
genic in mice (Yan et al., 2004). In fact, the truncated
AML1/ETO was more highly leukemogenic than the full-
length protein and could cooperate with full-length AML1/
ETO to induce a rapid disease (Yan et al., 2004, 2006). One
of the genes whose expression was most highly upregu-
lated by both AML1/ETO (24-fold) and the W692 mutant
(23-fold) was high mobility group protein 2 (Hmga2).
HMGA proteins are small, architechural transcription fac-
tors involved in proliferation, apoptosis, differentiation,
and senescence (Narita et al., 2006; Reeves, 2001). Upre-
gulation ofHMGA2 expression has been found in a variety
of solid tumors in humans, and chromosomal rearrang-494 Cancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc.ments of HMGA2 are common in benign mesenchymal
tumors (Reeves, 2001). In senescent cells, HMGA was
shown to repressMCMs and cyclin A (Narita et al., 2006).
As shown in Table 2, cyclin A and MCMs 2, 3, 6, 7, and 8
are all downregulated by AML1/ETO as well as the mutant
AML1/ETO, albeit to a lesser extent, suggesting increased
HMGA2may well contribute to the AML1/ETO phenotype.
In summary, our results demonstrate that recruitment of
SMRT/N-CoR by the MYND domain contributes to the
transcriptional dysregulation caused by AML1/ETO and
to its repression of both proliferation and granulocyte dif-
ferentiation. The two-hit hypothesis for leukemia develop-
ment posits the need for both a block in differentiation and
a proliferative advantage (Gilliland and Tallman, 2002). It is
well established in mousemodels that AML1-ETO by itself
does not cause leukemia but requires additional cooperat-
ing mutations (Grisolano et al., 2003; Schessl et al., 2005;
Schwieger et al., 2002). Full-length AML1-ETO can clearly
Cancer Cell
Structure/Function of MYND Domain in AML1-ETOachieve the block in differentiation posited in the two-hit
model but is not able to provide the necessary proliferative
advantage. The recent demonstration by Zhang and co-
workers (Yan et al., 2004, 2006) that a truncated form of
AML1-ETO lacking the Nervy and MYND domains causes
leukemia, unlike AML1-ETO itself, suggests that a trun-
cated form of the protein can provide both the differentia-
tion block and the proliferative advantage necessary. This
is in good agreement with our results showing that loss of
SMRT/N-CoR binding to the MYND domain results in in-
creased proliferation, i.e., abrogation of MYND domain
function provides or contributes significantly to the neces-
sary proliferative advantage. The loss of this domain in the
truncation in the case of truncated AML1-ETO or altered
regulation, perhaps by phosphorylation, of this domain
in the case of other cooperating mutations may provide a
mechanism to achieve both hits through one protein. In
the latter case, the signaling pathways involved in such
regulation may therefore prove to be useful targets for
therapeutic intervention.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
All proteins were cloned, expressed, and purified using standard pro-
cedures (details in Supplemental Data).
Peptide Binding Measurements by Fluorescence Anisotropy
All fluorescence experiments were carried out at 25Con a FluroMax-3
fluorescence spectrophotometer (Horiba Jobin Yvon, Edison, NJ) with
an external temperature control unit. The concentration of fluorescein-
labeled peptides was kept at 5 mM during SMRT binding epitope
screening and 1 mM during MYND mutant binding experiments. Pep-
tides 12 aa in length with 9 aa overlaps spanning the entire SMRT se-
quence and with an N-terminal fluorescein were employed for epitope
mapping. The excitation and emission wavelengths were set to 494 nm
and 525 nm, respectively. Anisotropy values were averaged over 1 s
during the epitope screening experiments and over 5 s during the
MYND mutant binding experiments following a 2 min pre-equilibration
at 25C.
Peptide Binding Measurements by Isothermal
Titration Calorimetry
ITC experiments were carried out on a MCS-ITC isothermal titration
calorimetric system (MicroCal, Northampton MA) at 26C. The calori-
metric cell containing 170 or 257 mM MYND domain was titrated with
3.3 mM SMRT (1101–1113: YG-TISNPPPLISSAK) or 2 mM N-CoR
(N-CoR 1000–1011; YG-TRPPPPLIPSSK) peptides. Both MYND and
SMRT/N-CoR were thoroughly dialyzed into the same buffer contain-
ing 25 mM Bis-Tris (pH 7.5), 0.1 M NaCl, 1 mM DTT, and 50 mM ZnCl2.
Data were analyzed using Origin 7.0 (OriginLab, Northampton MA).
Analytical Ultracentrifugation
Sedimentation velocity runs were done at 20C using an AN-60
titanium rotor (Beckman) and SedVel60 centerpieces with 1.2 cm path
length and quartz windows. The runs were done at 35,000 rpm, and
interference scans were acquired using Beckman software. Analyses
were done using Sedfit (Schuck, 2000) with (96 resolution, 0.5–10 s)
radial and time independent noise at 95% confidence intervals.
NMR Spectroscopy
Samples for structure determination were prepared in 25 mM Bis-Tris
(pH 6.8), 50 mM ZnCl2, and 1 mM DTT. One hundred millimolar NaCl
was included in the buffer for charged-gel samples to alleviate linebroadening due to protein-gel interaction. Data were collected on
a 600 MHz Varian Inova Spectrometer (Palo Alto, CA) equipped with
a cryogenically cooled probe at 32C. Resonance assignment and
NOESY data collection were carried out using standard experiments.
For alignment, a negatively charged gel compressed to 4% concen-
tration and consisting of 50% 2-acrylamido-2-methyl-1-propanesul-
fonic acid and 50% acrylamide (50  M) and a zwitterionic charged
gel compressed to 4% concentration consisting of 50% of a 1:1 mix-
ture of (3-acrylamidopropyl)-trimethylammonium chloride/acrylic acid
and 50% acrylamide (50 + MA) were employed (Cierpicki and Bushw-
eller, 2004). Three types of dipolar couplings, 1DHN,
1DNC0, and
1DC0Ca,
were measured using IPAP (Ottiger et al., 1998) and 3D HNCO-based
experiments (Yang et al., 1999). All NMR spectra were processed and
analyzed using NMRPipe and Sparky (T.D. Goddard and J.M. Kneller,
University of California, San Francisco).
Structure Calculations
Structure calculations were carried out using the simulated annealing
protocol in CNS (Brunger et al., 1998). Details are provided in the Sup-
plemental Data.
Retroviral Transductions
Mutated AML1/ETO proteins were transferred from pBluescript into
the MIGR1 vector (Pear et al., 1998), and retroviruses were prepared
as described previously (Liu et al., 2006). Primary bone marrow mono-
nuclear cells were harvested from 5- to 6-week-old C57BL/6 mice
(Jackson Labs, Bar Harbor, ME) and subjected to immunomagnetic
negative selection using the Lineage cell depletion Kit (Miltenyi Bio-
tech, Auburn, CA). For the microarray experiments, the Lin cells were
further enriched for Sca1+ cells by positive selection using the Anti-
Sca-1 MicroBead Kit (Miltenyi Biotech). Cells (6 3 105 in 3 ml) were
plated in ultralow adhesion 6-well plates (Costar, Corning, NY) and in-
cubated overnight at 37C, 5% CO2 in transplant media (RPMI, 20%
FCS, penicillin and streptomycin, 10 ng/ml IL-3, 20 ng/ml IL-6 [R&D
Systems, Minneapolis, MN], 10 ng/ml SCF [Stem Cell technologies,
Vancouver, Canada]). Twelve hours later, 6 3 105 cells in 2 ml of fresh
transplant media were added to 6-well plates (Cellstar, GBO, NC)
coated with 100 mg Retronectin (Takara, Madison, WI). Retroviral su-
pernatants (2 ml), 4 ml of 40 mg/ml polybrene and 40 ml 1 M Hepes
were added to each well, and the cells were centrifuged for 90 min
at 1400 g, 37C. Cells for microarray experiments were subjected to
a second round of transduction 24 hr later as described above.
Granulocyte Differentiation
Granulocyte differentiation was assessed as described previously (Liu
et al., 2006).
Cell-Cycle Kinetics
BrdU incorporation by Lin bone marrow cells was assessed 48 hr af-
ter retroviral transduction according to the manufacturer’s instructions
(APC-BrdU flow kit, BD PharMingen, San Diego, CA). Cells were incu-
bated with 30 mMBrdU for 1 hr and stained with Allophcocyanin (APC)-
conjugated anti-BrdU antibody and 7-AAD. Data were collected on a
FACSCalibur (BD Biosciences, San Jose CA) and analyzed by FlowJo
(version 6.1.1, Tree Star, San Carlos, CA).
Microarray Analyses
Lin Sca1+ bone marrow cells independently transduced with MIGR1
(three separate pools), AML1/ETO (three pools), or AML1/ETO W692A
(four pools) were stained 48 hr later with PE conjugated anti-CD117
(clone 2B8, BD Bioscience), PerCp-Cy5.5 conjugated Streptavidin
(BD Bioscience), APC-conjugated anti-Sca1 (clone D7, Ebiosciences,
SanDiego, CA), and biotin-conjugated antibody cocktail (Miltenyi Bio-
tech). Lin Sca-1+ c-kit+ GFP+ cells were isolated on a FACSAria (Bec-
ton Dickinson). Approximately 25,000 cells were collected for each
sample. Cells were sorted into 600 ml of RNA lysis buffer (Qiagen buffer
RLT with b-mercaptoethanol, Valencia CA), incubated at 42C for 1 hr,
and vortexed for 1 min to facilitate cell lysis. Total RNA was extractedCancer Cell 11, 483–497, June 2007 ª2007 Elsevier Inc. 495
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cording to the manufacturer’s protocol. Total RNA quantity was mea-
sured using a ND-1000 spectrophotometer (Nano-Drop, Wilmington,
DE), and RNA integrity was verified on an Agilent Bioanalyzer using
a RNA 6000 Pico chip (Agilent Technologies, Santa Clara, CA). Tomin-
imize potential sample variability, 50 ng of total RNA from each sample
was used as template for T7-based linear RNA amplification (RiboAmp
kit, Arcturus, Mountain View, CA). Poly-inosinic poly-cytidilic acid
(200 ng, Sigma, St. Louis, MO) was added as a carrier during the first
round of cDNA synthesis. 1 mg of double-stranded cDNA derived from
a second round of cDNA synthesis (RiboAmp kit) was used as template
for generating biotinylated cRNA (BioArray High Yield Transcription kit,
Enzo Life Sciences, Farmingdale NY). Labeled cRNAwas then DnaseI-
treated and purified on Rneasy minicolumns (Qiagen). Samples were
submitted to the Norris Cotton Cancer Center and Dartmouth Medical
School Microarray Shared Resource facility for fragmentation and
hybridization to Mouse Whole Genome 430 2.0 arrays (Affymetrix,
Santa Clara, CA).
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dure, five supplemental figures, and two supplemental tables and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/11/6/483/DC1/.
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